As recently as late May, as part of a discussion on the coronavirus crisis, the White House continued to insist publicly that hydroxychloroquine is “safe” to use. As of yesterday, the FDA delivered a very different message.
The Food and Drug Administration rescinded the emergency use authorization for hydroxychloroquine to treat hospitalized COVID-19 patients on Monday, saying the drug carries too many risks without any apparent benefit. The authorization was first issued in March, and applied to patients hospitalized with the illness and those in clinical trials. In April, the FDA warned doctors against prescribing the drug to COVID-19 patients outside of those settings.
And yet, even after the FDA’s move, Donald Trump spoke at a White House event where he continued to pontificate on the controversial medication. “I can’t complain about it. I took it for two weeks, and I’m here,” the president said. He added, “We’ve had some great studies,” none of which he identified.
Despite the latest evidence, Trump went on to say, “I’ve had so many people that were so thrilled with the results from hydroxy.”
I can appreciate why the president has found himself in a difficult position. Desperate for a possible “game-changer” — a label he applied to hydroxychloroquine weeks ago — Trump encouraged Americans to take the medication, personally vouching for its safety. It now seems quite obvious that his efforts to hype the drug were wildly irresponsible. An explanation is in order.









